Equities Analysts Issue Forecasts for Genmab A/S Q1 Earnings

Genmab A/S (NASDAQ:GMAB - Free Report) - Analysts at HC Wainwright issued their Q1 2025 EPS estimates for Genmab A/S in a research report issued on Thursday, January 23rd. HC Wainwright analyst R. Selvaraju forecasts that the company will earn $0.18 per share for the quarter. HC Wainwright has a "Buy" rating and a $50.00 price objective on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.28 per share. HC Wainwright also issued estimates for Genmab A/S's Q2 2025 earnings at $0.39 EPS, Q3 2025 earnings at $0.43 EPS, Q4 2025 earnings at $0.49 EPS and FY2025 earnings at $1.50 EPS.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The company had revenue of $816.10 million for the quarter, compared to analysts' expectations of $838.20 million. During the same period in the previous year, the firm earned $0.47 EPS.

Several other brokerages also recently commented on GMAB. Redburn Atlantic initiated coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a "buy" rating on the stock. Sanford C. Bernstein raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, December 20th. Finally, BMO Capital Markets reaffirmed an "outperform" rating and issued a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $45.20.

Genmab A/S Stock Performance

NASDAQ:GMAB traded down $0.16 during mid-day trading on Friday, reaching $21.13. The stock had a trading volume of 583,120 shares, compared to its average volume of 1,072,235. The stock has a market capitalization of $13.98 billion, a P/E ratio of 20.51, a P/E/G ratio of 0.57 and a beta of 0.97. Genmab A/S has a one year low of $19.85 and a one year high of $31.88. The firm has a 50 day moving average price of $21.07 and a two-hundred day moving average price of $23.96.

Institutional Trading of Genmab A/S

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. raised its holdings in Genmab A/S by 94.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company's stock worth $636,000 after purchasing an additional 12,654 shares during the period. HighTower Advisors LLC purchased a new stake in shares of Genmab A/S during the third quarter worth about $273,000. Verition Fund Management LLC purchased a new position in Genmab A/S in the 3rd quarter valued at about $709,000. FMR LLC boosted its holdings in Genmab A/S by 13.5% in the 3rd quarter. FMR LLC now owns 278,194 shares of the company's stock worth $6,782,000 after buying an additional 33,076 shares during the last quarter. Finally, Natixis Advisors LLC increased its stake in Genmab A/S by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company's stock worth $5,036,000 after buying an additional 47,437 shares in the last quarter. Institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.